# Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

> **NCT04190433** · PHASE2 · WITHDRAWN · sponsor: **Mayo Clinic**

## Conditions studied

- Breast Carcinoma
- Hematopoietic and Lymphoid Cell Neoplasm
- Lymphoma
- Sarcoma

## Interventions

- **DRUG:** Carvedilol
- **DRUG:** Lisinopril
- **DRUG:** Pravastatin
- **DRUG:** Spironolactone

## Key facts

- **NCT ID:** NCT04190433
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09-01
- **Primary completion:** 2023-04-18
- **Final completion:** 2023-04-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Administratively closed due to low/no accrual
- **Last updated:** 2023-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04190433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04190433, "Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04190433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*